Within3 Appoints Kyle Clifton as Vice President, Customer Value & Growth
Market access and commercialization strategist with more than 18 years guiding biopharma products from evaluation to
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Within3, whose platform is trusted by all of the top 20 pharma companies to turn public data, private data, and expert networks into decision-ready evidence, today announced the appointment of Kyle Clifton as Vice President, Customer Value & Growth. In this role, Clifton will help clients define, measure, and receive the value that Within3’s technology and expertise provide. He brings more than 18 years of experience in biopharma commercial strategy, pricing, and market access, guiding assets from early evaluation through U.S. commercialization across rare diseases and oncology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117347377/en/
Within3 welcomes Kyle Clifton as its new VP, Customer Value & Growth
Most recently, Clifton served as Managing Director at Red Nucleus, a global life sciences agency, where he led market access and commercial strategy engagements across various therapeutic areas. Earlier, he held consulting roles at Promidian Consulting, Boston Healthcare Associates, and Covance, and began his career on the front lines of the market as a Professional Sales Representative at Merck and an Account Manager for Medicare Part D at CVS Caremark. Clifton holds a Master of Business Administration and a Master of Health Sector Management from the W. P. Carey School of Business at Arizona State University, and a Bachelor of Arts in Business Administration from Rhodes College.
“Every client conversation comes back to two questions: how will this therapy reach the patients who need it, and what will make it succeed?” said Erin Mistry, Chief Executive Officer of Within3. “Kyle has spent his career answering both, across commercial strategy, M&A, pricing, access, and launch. He turns evidence into value that payers, providers, and patients recognize. We are excited to have him partnering with our clients and their investors to drive broader access and stronger commercial results.”
“Growth comes from clients who see measurable value in the partnership and keep finding new ways to put it to work,” said Ira Daly, who recently joined Within3 as Chief Operating Officer. “Kyle has worked alongside biopharma teams on their toughest decisions: which indication to prioritize, how to price an asset, and what evidence will drive payer access and HCP adoption. He pairs deep market access and commercial expertise with a talent for building value through creative solutions, which will help our clients turn evidence into specific actions that capture opportunities and mitigate risk.”
“I’ve spent my career helping biopharma teams make high-stakes commercial, pricing, and access decisions, often with an incomplete picture of the market,” said Clifton. “Within3 closes that gap with a connected, real-time view of the clinical and commercial landscape. I’m excited to help clients leverage insights from this technology and see its impact on outcomes, access, and, ultimately, the patients these therapies are meant to serve.”
As Vice President, Customer Value & Growth, Clifton will connect Within3’s decision-ready evidence directly to the commercial and market access questions that shape clients’ portfolios, identify new opportunities to apply it across lifecycle stages, and bring market access and commercialization expertise to client partnerships.
About Within3
Trusted by all of the top 20 pharmaceutical companies, Within3 delivers decision-ready evidence by uncovering the hidden influencers shaping clinical practice and capturing market shifts as they emerge, all in a shared, compliant view.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117347377/en/
Media gallery


